Search

Your search keyword '"Jan Beyer-Westendorf"' showing total 214 results

Search Constraints

Start Over You searched for: Author "Jan Beyer-Westendorf" Remove constraint Author: "Jan Beyer-Westendorf" Topic medicine.medical_specialty Remove constraint Topic: medicine.medical_specialty
214 results on '"Jan Beyer-Westendorf"'

Search Results

1. Detection of Direct Oral Anticoagulants in Patient Urine Samples by Prototype and Commercial Test Strips for DOACs - A Systematic Review and Meta-analysis

2. Secondary Immune Thrombocytopenia (ITP) Associated with ChAdOx1 Covid-19 Vaccination – A Case Report

3. The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation

4. 5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry

6. Definition of haemostatic effectiveness in interventions used to treat major bleeding

7. Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study

8. Thromboembolische Komplikationen bei COVID-19

9. Systematic Literature Review of Randomized Trials Comparing Antithrombotic Therapy Following Revascularization Procedures in Patients With Peripheral Artery Disease

10. Anticoagulant therapy for splanchnic vein thrombosis

11. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data

12. Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care

13. Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry

14. Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism: Rationale and design of the PLATO-VTE study

15. Cancer‐Associated ThrOmboSIs – Patient‐Reported OutcoMes With RivarOxaban (COSIMO) – Baseline characteristics and clinical outcomes

16. Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation. Observational registry

17. Two-year outcomes of patients with atrial fibrillation treated with rivaroxaban: results from RIVER registry

18. Rivaroxaban dosing in patients with atrial fibrillation: results from the RIVER registry – is dosing according to renal function appropriate?

19. Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score

20. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism

21. Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin

22. DTI/DXI interferences with global coagulation tests in emergency hospital admissions - Results of the prospective Dresden NOAC Registry (NCT01588119)

23. DOACS in women: pros and cons

24. Longitudinal kidney function trajectories predict major bleeding, hospitalization and death in patients with atrial fibrillation and chronic kidney disease

25. Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE

26. Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill

27. Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study

28. Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding

29. Reproductive issues in women on direct oral anticoagulants

30. First Trimester Anticoagulant Exposure and Adverse Pregnancy Outcomes in Women with Preconception Venous Thromboembolism: A Nationwide Cohort Study

31. Every 6 seconds in Europe

32. Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients

33. Direct Oral Anticoagulants in Atrial Fibrillation: Practical Considerations and Remaining Issues

34. Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high- and low-dose rivaroxaban with aspirin

35. Hormonal ContraceptionGuideline of the DGGG, OEGGG and SGGG (S3 Level, AWMF Registry Number 015/015, January 2020)

36. Anticoagulation treatment in cancer-Associated venous thromboembolism: Assessment of patient preferences using a discrete choice experiment (cosimo study)

37. Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism – The COSIMO study

38. Abstract 13927: Advanced Age and Preferential Use of Vitamin K Antagonists in Severe Renal Impairment: First Results of the XARENO Registry in Patients With Non-valvular Atrial Fibrillation and Non-dialysis Dependent Advanced Chronic Kidney Disease

39. Survival and quality of life after early discharge in low-risk pulmonary embolism

40. Definition of major bleeding: Prognostic classification

41. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data

42. Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry

43. Rates, management and outcome of bleeding complications during edoxaban therapy in daily care - results from the DRESDEN NOAC REGISTRY

44. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation

45. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial

46. Comparative risk of major bleeding with rivaroxaban and warfarin: Population‐based cohort study of unprovoked venous thromboembolism

47. The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients

48. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study

49. Betrixaban for prevention of venous thromboembolism in acute medically ill patients

50. Risk of recurrent venous thromboembolism according to baseline risk factor profiles

Catalog

Books, media, physical & digital resources